| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Royalty | - | 57,605 | - | - |
| Product | - | 118,329 | - | - |
| Total revenues | 211,007 | - | 1,176,096 | 196,786 |
| Collaboration And License Revenue | - | 2,941 | - | - |
| Change in the fair value of contingent consideration | - | - | 800 | -700 |
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 15,781 | 11,420 | 12,862 | 10,848 |
| Total revenues | - | 178,875 | - | - |
| Amortization of acquired intangible assets | 7,534 | 4,061 | 3,798 | 3,036 |
| Total revenues-Manufacturing | - | 0 | - | - |
| Research and development | 100,158 | 112,990 | 108,973 | 161,412 |
| Selling, general and administrative | 84,046 | 85,262 | 80,961 | 73,456 |
| Tangible asset impairment and losses (gains) on transactions, net | -472 | -99 | -77 | -1,844 |
| Total operating expenses | 207,991 | 213,832 | 205,871 | 251,296 |
| Income (loss) from operations | 3,016 | -34,957 | 970,225 | -54,510 |
| Interest expense, net | -32,592 | -30,358 | -34,092 | -41,609 |
| Other income (expense), net | 6,502 | -5,737 | -6,305 | -1,872 |
| (loss) income before income tax benefit (expense) | -23,074 | -71,052 | 929,828 | -97,991 |
| Income tax benefit (expense) | -38,970 | -6,203 | 63,266 | 8,663 |
| Net income (loss) attributable to common stockholders | 15,896 | -64,849 | 866,562 | -106,654 |
| Earnings per share, basic | 0.2 | -0.83 | 11.09 | -1.39 |
| Earnings per share, diluted | 0.2 | -0.83 | 10.04 | -1.39 |
| Weighted average number of shares outstanding, basic | 78,471,119 | 78,151,240 | 78,115,836 | 76,925,523 |
| Weighted average number of shares outstanding, diluted | 87,115,369 | 78,151,240 | 86,385,922 | 76,925,523 |
PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT)